riesen Chance: DNAP for Pre-Clinical Evalution - 500 Beiträge pro Seite

[brokersvenja007]

DNAPrint Selects Proteos to Manufacture PT-401
for Pre-Clinical Evaluation

wer interesse hat setzt sich mal einwenig mit dem wert auseinander,.....jahrelange mühen scheinen endlich bezahlt zu werden.
wenn jetzt noch die ergebnisse passen, dann werden wir uns von diesen kursen schnell verabschieden.

wer jetzt dabei ist kann bei einem riesen ran dabei sein.

informiert euch und verdient mit...
svenja


14 June 2005, 09:44am ET

SARASOTA, Fla., June 14 /PRNewswire-FirstCall/ -- DNAPrint genomics, Inc. (BBNAP) (the "Company") today announced that it has selected Proteos, Inc. to manufacture the first batch of its new therapeutic candidate PT-401 (Super EPO dimer) for pre-clinical testing.

"Proteos has 20 years of experience in protein and peptide chemistry and has proven its ability as a Contract Research Organization (CRO) dealing with biologically complex therapeutics," stated DNAPrint Chairman and Chief Medical Officer Hector Gomez, M.D., Ph.D. "The selection of Proteos is the culmination of a competitive bidding process solicited by DNAPrint management. In addition, Proteos` staff has previously worked with erythropoietin (EPO), the simpler, monomer form of the drug that major pharmaceutical companies currently have on the market."

DNAPrint announced in April that it has acquired an exclusive worldwide license from Harvard Medical School`s Beth Israel Deaconess Medical Center (BIDMC) to develop a new, more potent and longer acting form of the anemia drug erythropoietin. DNAPrint is working on the project with Dr. Arthur J. Sytkowski, Director for the Laboratory for Cell and Molecular Biology, Division of Hematology and Oncology at Beth Israel Deaconess. The PT-401 to be manufactured by Proteos will be used to generate pre-clinical data required for an Investigational New Drug (IND) application as required by the U.S. Food and Drug Administration.

"We are now beginning the clinical development process and today`s announcement is a major step for DNAPrint toward compiling the data for its first IND application," stated President and Chief Executive Officer Richard Gabriel. "Dr. Sytkowski, who has worked his entire career on Erythropoietin and similar molecules, and Dr. Gomez selected Proteos for its technical skills and background and will monitor the data collection very closely."

DNAPrint also announced that it has agreed to a six-month contract with Dr. Sytkowski to provide continued support for the completion of the PT-401 clinical research program. "Dr. Sytkowski holds eight patents covering this technology and is the author of a book on the subject, `Erythropoietin, Blood, Brain and Beyond.` He brings a knowledge base to the development of our licensed product, and his agreement is structured to give him appropriate incentives to help move the product through clinical development," Dr. Gomez stated.

About Proteos

Mentioned Last Change
DNAP 0.0131 0.0012dollars or (8.39%)
Proteos, Inc. ( http://www.proteos.net ) is a provider of high quality proteins and peptides for enabling and facilitating drug discovery. The Proteos Process includes target identification, expression using various cell lines, purification and production of proteins. Unique protein services include Expression in baculovirus, mammalian cells, and E coli, Refolding of proteins from inclusion bodies, Purification, and Assay Development. Peptide services include Design and Modification, and Antigen Design, Production and Purification. Proteos, based in Kalamazoo, Mich., was founded by eight scientists following the August 2002 acquisition of Pharmacia by Pfizer, Inc.

About DNAPrint genomics, Inc.

DNAPrint genomics, Inc. ( http://www.dnaprint.com ) is a developer of genomics-based products and services focused on drug development, pharmacogenomic diagnostic tests, forensics technology and consumer genetic tests. The Company`s first theranostic product (drug/test combination) is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Currently in pre-clinical development, PT-401 will be targeted to patients with a genetic profile indicating their propensity to have the best clinical response.

Forward-Looking Statements

All statements in this press release that are not historical are forward- looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint`s products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward- looking statements contained herein to reflect any change in DNAPrint`s expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

[luto9]

War heute morgen schon bekannt

[brokersvenja007]

wer dabie sein will, der kann jetzt noch günstig einsteigen,..langzeit-invest

grüße
svenja

[Leo02]

Schön wärs....
mal sollte nur fairerweise den anstehenden RS erwähnen

[FCHennes]

Den RS sollte man erwähnen, denn dann wird es hier noch mehr nach oben gehen!!!

DNAP ist die beste Geldanlage, die ich zur Zeit kenne.

FCHennes

[luto9]

stellt sich nur die Frage, ob ein Splitt von 20-1
viel bringt?

[luto9]

DNAPrint buying stake in drugmaker

BY MARGARET ANN MIILLE



SARASOTA -- DNAPrint Genomics Inc. is tapping into a drug development pipeline by becoming the majority owner of a German pharmaceutical company.

DNAPrint announced this week that it has agreed to acquire 51.77 percent of Biofrontera AG, a company based in Keverkusen and Heidelberg. The money for the deal will come from the Dutchess Private Equity Fund, which will buy up to $35 million of DNAPrint`s stock over two years.

DNAPrint has agreed to invest about $25 million during the same length of time in Biofrontera shares, representing a 51.77 percent equity interest.

"This is what I have been waiting for for the past four years, to reach this stage of legitimacy," said Tony Frudakis, the company`s founder and chief science officer. "From the very beginning, we`ve wanted to become a drug company, not just a data company that makes neat genetic tests."

DNAPrint, which has developed genetic tests that genealogists and forensic experts use to determine a person`s racial mix, said the Biofrontera deal will give DNAPrint access to drugs already under development and allow the two companies to share technology.

The focus will be on "theranostics," which blend genomics tests with drugs to yield the best results in specific groups of people.

Biofrontera`s lead candidate for development is a drug called "BF-Derm1," which is in clinical trials for treating chronic itching and scratching. Frudakis said that drug so far has shown a 40 percent improvement when compared with a placebo in reducing clinical symptoms in all patients.

Biofrontera, which focuses on developing treatments for inflammation and central nervous system diseases, also is in the early stages of developing a drug to treat and prevent migraines.

DNAPrint said it will continue selling its ancestry tests, called DNAWitness when marketed to the forensics market and ANCESTRYbyDNA2.5 when sold to the public.

But it intends to wrap up its research and market diagnostic tests for determining what existing drugs work the best for certain patients.

"Most of our efforts in the future will focus on developing our pipeline of new drugs," Frudakis said.

The two companies plan to eventually seek out a manufacturer when their drugs reach the production stage.

DNAPrint said the agreement with Dutchess, a limited partnership based in Boston, was arranged by Athena Capital Partners Inc., a private merchant bank in Tampa.

Frudakis Continued
1 | 2 | Next >>
DNAPrint buying stake in drugmaker

BY MARGARET ANN MIILLE



(Page 2)
. . . Frudakis said the acquisition eventually should boost investor confidence and buying activity in his company`s over-the-counter stock.

At the close of trading Thursday, shares were selling for 1.9 cents, down from 2.2 cents the previous day.

"Investors value data companies, basic science companies, much lower than they do pharmaceutical companies," Frudakis said. "The money in this business is in selling medicine."

http://www.heraldtribune.com/apps/pbcs.dll/article?AID=/2004…